Global Scales for Cognitive Screening in Parkinson’s Disease: Critique and Recommendations Matej Skorvanek, MD, PhD, 1,2 * Jennifer G. Goldman, MD, MS , 3 Marjan Jahanshahi, PhD, 4 Connie Marras, MD, PhD, 5 Irena Rektorova, MD, PhD, 6 Ben Schmand, PhD, 7 Erik van Duijn, MD, PhD, 8 Christopher G. Goetz, MD, 3 Daniel Weintraub, MD, 9 Glenn T. Stebbins, PhD, 3 Pablo Martinez-Martin, MD, PhD, 10 and the members of the MDS Rating Scales Review Committee 1 Department of Neurology, Safarik University, Kosice, Slovakia 2 Department of Neurology, University Hospital of L. Pasteur, Kosice, Slovakia 3 Rush University Medical Center, Department of Neurological Sciences, Section of Parkinson Disease and Movement Disorders, Chicago, Illinois, USA 4 Sobell Department of Motor Neuroscience & Movement Disorders and the National Hospital for Neurology & Neurosurgery, London, UK 5 Morton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson’s Disease, Toronto Western Hospital, Toronto, Ontario, Canada 6 Applied Neuroscience Research Group, Central European Institute of Technology, CEITEC, Masaryk University, Brno, Czech Republic 7 Department of Psychology, University of Amsterdam, Amsterdam, The Netherlands 8 Department of Psychiatry, Leiden University Medical Centre, Leiden, and Centre of Mental Health Care Delfland, Delft, Netherlands 9 Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania and Parkinson’s Disease and Mental Health Research, Education and Clinical Centers (PADRECC and MIRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA 10 National Centre of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain ABSTRACT: Background: Cognitive impairment is a common nonmotor manifestation of Parkinson’s dis- ease, with deficits ranging from mild cognitive difficul- ties in 1 or more of the cognitive domains to severe dementia. The International Parkinson and Movement Disorder Society commissioned the assessment of the clinimetric properties of cognitive rating scales measur- ing global cognitive performance in PD to make recom- mendations regarding their use. Methods: A systematic literature search was conducted to identify the scales used to assess global cognitive performance in PD, and the identified scales were reviewed and rated as “recommended,” “recommended with caveats,” “suggested,” or “listed” by the panel using previously established criteria. Results: A total of 12 cognitive scales were included in this review. Three scales, the Montreal Cognitive Assessment, the Mattis Dementia Rating Scale Second Edition, and the Parkinson’s Disease-Cognitive Rating Scale, were classified as “recommended.” Two scales were classified as “recommended with caveats”: the Mini-Mental Parkinson, because of limited coverage of executive abilities, and the Scales for Outcomes in Par- kinson’s Disease-Cognition, which has limited data on sensitivity to change. Six other scales were classified as “suggested” and 1 scale as “listed.” Conclusions: Because of the existence of “recommended” scales for assessment of global cognitive performance in PD, this task force suggests that the development of a new scale for this purpose is not needed at this time. However, global cognitive scales are not a substitute for comprehen- sive neuropsychological testing. V C 2017 International Par- kinson and Movement Disorder Society Key Words: Parkinson’s disease; cognitive; demen- tia; rating scales; clinimetric Cognitive impairment in Parkinson’s disease (PD) ranges from mild cognitive difficulties in 1 or more of the cognitive domains, present sometimes even early in the disease course, 1 to severe dementia, most typically occurring after at least several years of disease. 2,3 Cumulative prevalence rates of Parkinson’s disease dementia (PD-D) may reach up to 80% after 20 years ------------------------------------------------------------ *Correspondence to: Matej Skorvanek, MD, PhD, Dept. of Neurology, Safarik University and University Hospital of L. Pasteur, Trieda SNP 1, 040 11 Kosice, Slovakia; mskorvanek@gmail.com Relevant conflicts of interest/financial disclosures: nothing to report. Funding agencies: none. Received: 9 August 2017; Revised: 19 September 2017; Accepted: 16 October 2017 Published online 00 Month 2017 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.27233 REVIEW Movement Disorders, Vol. 00, No. 00, 2017 1